BioSpace News Archive

Evogene Ltd. today announced its financial results for the first quarter period ending March 31, 2023.

Veeva Systems (NYSE: VEEV) today announced Veeva Link MedTech , a data application developed for medtech companies to identify scientific experts, personalize engagement, and map activities across the healthcare ecosystem.

Boston Pharmaceuticals today announced that new results from its ongoing Phase 2a study evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH) were accepted as a late-breaking poster presentation at the European Association for the Study of the Liver International Liver Congress, June 21-24 in Vienna, Austria.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24, 2023, in Washington, DC.

Affinia Therapeutics today announced the presentation of new preclinical data on novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS).

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, announced the appointment of Arun Balakumaran, M.D., Ph.D., as Chief Medical Officer, effective 22 May.

VYNE Therapeutics Inc. announced that members of management will attend the Biotechnology Innovation Organization International Convention, taking place June 5-8, 2023 at the Boston Convention & Exhibition Center in Boston, Massachusetts.

InspireMD, Inc. announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of Global Marketing in February 2023, InspireMD granted Mr. Gleason 256,450 shares of restricted stock and stock options to purchase 85,480 shares of InspireMD’s common stock.

HTG Molecular Diagnostics, Inc. announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA.

Poseida Therapeutics, Inc. today highlights its two oral and four poster presentations on the Company’s preclinical gene therapy programs and platforms at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually May 16 – 20, 2023.